Axel Hoos
Chairman en Cancer Research Institute .
Perfil
Axel Hoos was the founder of Imugene Ltd.
(founded in 2013) and held the title of Independent Non-Executive Director.
He is currently the Co-Chairman at Cancer Research Institute, Director at Nextpoint Therapeutics, Inc. (since 2023), and Trustee at Albert B.
Sabin Vaccine Institute, Inc. Dr. Hoos has previously served as the Chief Executive Officer & Director at Scorpion Therapeutics, Inc. (2021-2024), Senior Director-Clinical Development at Agenus, Inc. (2001-2005), Independent Director at TCR2 Therapeutics, Inc. (2020-2023), and Global Medical Lead-Immunology & Oncology at Bristol Myers Squibb Co. (2005-2011).
He has also held the position of Senior VP & Therapeutic Area Head-Oncology at GlaxoSmithKline Pharmaceuticals Ltd.
Dr. Hoos obtained his doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1997.
Cargos activos de Axel Hoos
| Empresas | Cargo | Inicio |
|---|---|---|
Albert B. Sabin Vaccine Institute, Inc.
 Albert B. Sabin Vaccine Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Albert B. Sabin Vaccine Institute, Inc. creates solutions to health threats. It works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the pervasive health care challenges. The company was founded in 1993 and is headquartered in Washington, DC. | Director/Board Member | - |
Cancer Research Institute
 Cancer Research Institute Medical/Nursing ServicesHealth Services Cancer Research Institute provides cancer immunotherapy services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded in 1953. Jill O'Donnell-Tormey has been the CEO of the company since 1987. | Chairman | - |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Director/Board Member | 21/03/2023 |
Antiguos cargos conocidos de Axel Hoos.
| Empresas | Cargo | Fin |
|---|---|---|
Scorpion Therapeutics, Inc.
 Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Chief Executive Officer | 04/01/2024 |
| TCR2 THERAPEUTICS INC. | Director/Board Member | 01/06/2023 |
| IMUGENE LIMITED | Founder | 19/11/2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2011 |
| AGENUS INC. | Corporate Officer/Principal | 01/01/2005 |
Formación de Axel Hoos.
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| AGENUS INC. | Health Technology |
| GLAXOSMITHKLINE PHARMACEUTICALS LIMITED | Health Technology |
| IMUGENE LIMITED | Health Technology |
| Empresas privadas | 5 |
|---|---|
Albert B. Sabin Vaccine Institute, Inc.
Albert B. Sabin Vaccine Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Albert B. Sabin Vaccine Institute, Inc. creates solutions to health threats. It works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the pervasive health care challenges. The company was founded in 1993 and is headquartered in Washington, DC. | Commercial Services |
Cancer Research Institute
Cancer Research Institute Medical/Nursing ServicesHealth Services Cancer Research Institute provides cancer immunotherapy services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded in 1953. Jill O'Donnell-Tormey has been the CEO of the company since 1987. | Health Services |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Technology |
Nextpoint Therapeutics, Inc.
Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Commercial Services |
- Bolsa de valores
- Insiders
- Axel Hoos
